阿瑪琳 AMRN 深 滬
已收盤 08-29 16:00:00 美东时间
15.04
-0.365
-2.37%
華盛通- 最 高15.41
- 今 開15.41
- 成交量 5.50万股
- 最 低 14.93
- 昨 收 15.405
- 總市值 3.11亿
- 52周最高 17.49
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 7.08
- 委 比 93.63%
- 總股本 2070.70万
- 歷史最高 522.40
- 量 比 1.04
- 振 幅 3.12%
- 歷史最低 7.08
- 每 手 1
- 風險率 2.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups
2025 ESC/EAS Guidelines reaffirm high-dose icosapent ethyl (IPE) as a Class IIA therapy for high-risk or very high-risk patients with elevated triglycerides. REDUCE-IT trial sub-analyses show significant reductions in cardiovascular events across various patient populations, including those with CKM syndrome, stratified by ApoB and triglyceride levels, and reduced hospitalizations and deaths. These findings support IPE's role in contemporary trea...
08-30 12:30
Amarin To Present New Data On Icosapent Ethyl's Cardioprotective Effects At ESC 2025, Highlighting Inflammation And Oxidation Mechanisms
Amarin Corporation plc (NASDAQ:AMRN) today announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2025, August 29th-September 1st, in Madrid, Spain, where new data will further illuminate
08-25 20:10
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025
Amarin Corporation will present new data on icosapent ethyl (IPE) at the ESC 2025 Congress in Madrid, highlighting its cardioprotective effects through inflammation reduction, lipoprotein oxidation, and CV risk mitigation in CKM syndrome. The findings include post hoc analyses from the REDUCE-IT trial and mechanistic studies on EPA's impact on Lp(a) oxidation and inflammasome activation. Amarin emphasizes IPE's clinical value in reducing cardiova...
08-25 12:00
苹果、微软、亚马逊、Meta财报来袭
作者丨Oliver Rodzianko 编译 | 华尔街大事件 本周科技巨头、能源巨头、金融公司、医疗保健行业领袖和消费者品牌将陆续发布大量财报。 焦点将集中...
07-28 20:40
Amneal to Report Second Quarter 2025 Results on August 5, 2025
Amneal Pharmaceuticals will release its second quarter 2025 financial results on August 5, 2025, before market open. A live audio webcast will be held at 8:30 a.m. ET, accessible via the company's Investor Relations website or by dialing 1 (833) 470-1428 with access code 627786. The company, headquartered in Bridgewater, NJ, specializes in developing, manufacturing, and distributing over 280 pharmaceuticals, with a focus on affordable medicines, ...
07-09 12:00
美股大行评级 | 潜在涨幅61.27%！Loop Capital上调英伟达目标价至250美元，维持"买入"评级
今日重点评级关注：Benchmark：维持特斯拉(TSLA)"买入"评级，目标价从350美元升至475美元>>
06-27 08:37
美股大行评级 | 潜在涨幅312.09%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
潜在涨幅312.09%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级；联邦快递遭多家机构下调目标价>>
06-26 08:38
美股牛股 | 纳比特大涨超36%，公司宣布为币安币储备大额可转换票据；内克塔治疗飙升逾150%
纳比特大涨超36%，公司宣布为币安币储备大额可转换票据；内克塔治疗飙升逾150%，皮炎药物临床试验结果良好；安霸拟考虑出售公司，隔夜涨超20%>>
06-25 19:15
Amarin Enters Licensing Agreement with Recordati
Amarin ( ($AMRN) ) just unveiled an announcement. On June 20, 2025, Amarin Corp...
06-24 19:29
Market-Moving News for June 24th
INM: 102% | InMed shares are trading higher after the company announced preclinical data showing INM-901 reduced neuroinflammation markers in an ex vivo Alzheimer's disease study. NA: 108% | Nano Labs
06-24 19:16
